Indication

Adult Patients With Adverse Risk Acute Myeloblastic Leukemia

1 clinical trial

1 product

Clinical trial

Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Status: Not yet recruiting, Estimated PCD: 2028-01-01

Product